5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

US6268369A · kind A · utility

Assignee

• Synaptic Pharmaceutical Corporation · US

Inventors

• Dhanapalan Nagarathnam · Bethany, US
• George Chiu · Bound Brook, US
• T. G. Murali Dhar · Newtown, US
• Wai C. Wong · Newark, US
• Mohammad R. Marzabadi · Ridgewood, US
• Charles Gluchowski · Mission Viejo, US
• Bharat Lagu · Maywood, US
• Shou Wu Miao · Edison, US

Key dates

• Filing date: May 16, 1997
• Grant date: Jul 31, 2001
• Expiry date: May 16, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention is directed to dihydropyrimidine compounds of the following formula: ##STR1## which are selective antagonists for human .alpha..sub.1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the .alpha..sub.1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.